nucleosid
hydrolas
main
marker
fml
complex
leishmania
donovani
antigen
licens
vaccin
prophylaxi
canin
viscer
leishmaniasi
dna
vaccin
mice
induc
immun
respons
vaccin
mongrel
dog
vaccin
prophylaxi
immunotherapi
high
dose
leishmania
chagasi
infect
x
infect
amastigot
untreat
control
develop
symptom
higher
parasitelymphocyt
ratio
smaller
dth
reaction
lower
proport
cell
sustain
cell
count
dog
prophylaxi
group
immunotherapi
treat
group
enlarg
dth
reaction
enhanc
sustain
lymphocyt
proport
also
detect
howev
without
reduct
symptom
parasitelymphocyt
ratio
indic
vaccin
suffici
potent
prevent
control
diseas
treatment
determin
higher
surviv
rate
antifml
antibodi
increas
vaccin
control
dog
antibodi
increas
vaccine
p
parasit
load
untreat
survivor
control
dog
parasit
felt
outsid
vaccin
dog
suggest
vaccin
treatment
succeed
reduc
leishmania
infect
burden
accordingli
untreat
control
dog
show
lower
level
ifn
actinrel
quantif
conclud
vaccin
induc
strong
prophylact
protect
milder
immunotherapeut
effect
high
dose
canin
experiment
infect
leishmania
chagasi
vaccin
fmlsaponin
vaccin
effici
prevent
immunotherapi
block
transmiss
canin
viscer
leishmaniasi
cvl
dog
human
nucleosid
hydrolas
kda
amino
acid
main
antigen
marker
fml
complex
cleav
nucleosid
import
dna
releas
free
purin
pyrimid
base
leishmania
replic
accord
relev
function
recent
recogn
import
conserv
phylogenet
marker
leishmania
genu
dna
vaccin
mice
induc
protect
cur
potenti
viscer
protect
coetan
leishmaniasi
develop
immun
respons
work
use
srd
dog
month
old
differ
brood
vaccin
rabi
canin
distemp
type
adenoviru
coronaviru
parainfluenza
parvoviru
leptospira
treat
antihelminth
drug
dog
healthi
seroneg
leishmania
antibodi
fmlelisa
assay
aim
avoid
bia
base
genet
determin
suscept
brood
random
draft
experiment
group
salin
prophylaxi
immunotherapi
prophylaxi
dog
vaccin
dose
g
plasmid
im
rout
day
dog
receiv
salin
day
anim
challeng
x
amastigot
l
chagasi
strain
maintain
passag
hamster
origin
isol
infect
dog
day
untreat
dog
alreadi
leishmaniaseroposit
symptomat
six
treat
immunotherapi
dose
g
vaccin
remain
untreat
control
sera
anim
assay
presenc
antifml
antibodi
cellular
immun
respons
evalu
assess
dth
respons
leishmani
lysat
proport
specif
lymphocyt
vitro
prolifer
pbmc
g
dog
also
monitor
clinic
symptom
score
parasitelymphocyt
ratio
giemsa
stain
smear
obtain
fine
needl
lymphnod
punctur
cohort
monitor
day
end
experi
parasit
load
survivor
dog
evalu
pbmc
cytokin
express
whole
blood
exvivo
assay
real
time
pcr
modifi
manna
et
al
use
primer
probe
repres
tabl
taq
man
furthermor
express
ifn
gamma
also
studi
real
time
pcr
vitro
prolifer
pbmc
one
dog
untreat
control
one
dog
immunoprophylaxi
group
day
parasit
load
also
obtain
absolut
quantificationr
time
pcr
statist
analysi
mean
compar
anova
analysi
simpl
factori
test
one
way
honestli
signific
differ
method
spss
window
test
signific
differ
group
also
use
confid
interv
averag
anim
includ
investig
treat
follow
guidelin
anim
experiment
usa
nation
institut
health
experi
done
accord
institut
guidelin
order
minim
anim
suffer
result
serolog
survey
summar
serolog
immun
respons
fml
start
infect
challeng
mean
seroposit
consequ
dna
vaccin
benefici
effect
vaccin
potenti
use
field
control
cvl
canid
zoonos
epidemiolog
campaign
remov
sacrific
dog
seroposit
leishmania
consid
infect
reservoir
diseas
anova
analysi
antifml
respons
show
signific
differ
time
anova
p
treatment
p
sinc
antifml
antibodi
increas
vaccin
prophylaxi
immunotherapi
control
dog
simultan
serolog
respons
recombin
protein
convers
specif
increas
prophylaxi
immunotherapi
treat
dog
anova
p
remain
low
infect
anim
anoth
benefici
effect
dna
vaccin
discrimin
infect
vaccin
anim
result
clinic
parasitolog
cell
immun
respons
dog
vaccin
dna
vaccin
untreat
control
summar
tabl
variabl
result
shown
averag
valu
record
month
period
experi
tabl
result
parasitelymphocyt
ratio
lymph
node
record
day
initi
vaccin
dose
anim
monthli
clinic
evalu
score
clinic
sign
prepar
consid
diamet
small
medium
larg
lymph
node
loss
weight
consid
mild
medium
sever
extrem
sever
asymptomat
case
receiv
detect
alopecia
onycogryphosi
skin
lesion
conjunct
pro
sal
attribut
valu
anaemia
oedema
attribut
ictericia
cachexia
cough
asthenia
cataract
nasal
purul
secret
attribut
valu
death
caus
cvl
attribut
valu
score
normal
undetect
small
medium
enlarg
lymph
node
respect
score
attribut
respect
mild
medium
sever
extrem
sever
loss
weight
lymphocyt
proport
correspond
count
obtain
vitro
prolifer
expect
develop
cvl
analysi
show
untreat
control
develop
symptom
higher
parasitelymphocyt
ratio
smaller
dth
reaction
lower
proport
cell
sustain
cell
count
compar
dog
prophylaxi
group
disclos
protect
potenti
prevent
vaccin
dna
vaccin
immunotherapi
treat
group
enlarg
dth
reaction
enhanc
sustain
lymphocyt
proport
also
detect
howev
without
reduct
symptom
parasitelymphocyt
ratio
compar
untreat
control
indic
dna
vaccin
dose
suffici
potent
control
diseas
provok
x
amastigot
obtain
dog
infect
futur
experi
done
smaller
infect
dose
use
investig
x
vitro
cultur
promastigot
order
better
defin
immunotherapeut
potenti
vaccin
high
infect
challeng
use
investig
also
respons
detect
high
mortal
tabl
spite
possibl
see
delay
mortal
rate
gener
vaccin
inde
averag
time
surviv
dog
treat
prophylaxi
immunotherapi
day
higher
respect
untreat
control
tabl
confirm
prevent
therapeut
effect
dna
vaccin
end
experi
day
leishmania
parasit
load
figur
cytokin
express
figur
assay
pbmc
whole
blood
respect
one
dog
prophylaxi
one
dog
control
group
pcr
real
time
techniqu
also
cytokin
express
measur
vitro
prolifer
pbmc
one
control
one
dog
prophylaxi
group
day
figur
day
parasit
load
untreat
survivor
control
dog
parasit
felt
outsid
vaccin
dog
figur
either
prophylaxi
immunotherapi
suggest
vaccin
treatment
succeed
reduc
leishmania
infect
burden
provok
artifici
high
parasit
challeng
x
infect
amastigot
accordingli
untreat
control
dog
show
ifn
actin
rel
quantif
lower
averag
vaccin
dog
although
felt
outsid
figur
rel
quantif
control
dog
respect
higher
vaccin
indic
global
enhanc
secret
ifn
due
dna
vaccin
treatment
measur
cytokin
express
specificlymphocyt
vitro
incub
figur
increas
ifn
decreas
express
observ
vaccin
dog
prophylaxi
rel
untreat
control
dog
indic
presenc
cell
immun
respons
decreas
vaccin
promis
result
sinc
cytokin
relat
progress
sever
cvl
analysi
result
conclud
vaccin
induc
strong
prophylact
protect
milder
immunotherapeut
effect
high
dose
canin
experiment
infect
leishmania
chagasi
